Skip to content

Biobehavioral Intervention in Gynecologic Oncology Patients

Psychological Changes in Cancer Patients Receiving a Biobehavioral Intervention: A Program Evaluation

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02454036
Enrollment
6
Registered
2015-05-27
Start date
2015-06-30
Completion date
2017-05-18
Last updated
2017-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neoplasms, Ovarian Neoplasms, Uterine Neoplasms, Vulva

Brief summary

Baseline self-report outcome measures will be completed and additional assessments will occur mid-treatment , post-treatment , 3 months following completion of all sessions, and 6 months following completion of all sessions. Patients and therapists will complete the evaluation measures in private (at home, in an office). At the University of Kentucky Markey Cancer Center, BBI treatment is offered in group and individual formats. The course of individual treatment varies and group treatment consists of 10 1.5-hour weekly sessions in the intensive phase, followed by 2 1.5-hour bi-weekly maintenance sessions. Individual treatment is one-on-one. In group treatment, there are typically 6-12 patients per group and 1 or 2 therapists. The intervention helps patients to learn adaptive coping strategies and how to apply them to daily stressors. Additional content discusses use of seeking information, enhancing social support, enhancing body esteem and intimacy, and maintaining positive changes.

Interventions

BEHAVIORALBBI intervention

Psychological intervention designed to reduce stress and enhance quality of life

Sponsors

Rachel Miller
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
21 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Females * Stage I-IV gynecologic cancer (including ovarian, uterine, cervical, vulvar, or vaginal cancer) * Undergoing active treatment or in remission and undergoing active surveillance; age ≥21 and ≤80 * Able to speak/read English.

Exclusion criteria

* Concurrent diagnosis of organic brain syndrome, dementia, mental retardation * Non-English speaking, or significant sensory deficit * Major mental illness (e.g., schizophrenia, psychotic disorder).

Design outcomes

Primary

MeasureTime frame
Sleep as measured by the Pittsburg Sleep Quality IndexUp to 6 months following completion of treatment
Pain as measured by the Brief Pain Questionnaire scoreUp to 6 months following completion of treatment
Fatigue as measured by the Fatigue Severity Index scoreUp to 6 months following completion of treatment
Emotional distress as measured by Profile of Mood States scoreUp to 6 months following completion of treatment
Cancer specific traumatic stress as measured the by Impact of Events Scale scoreUp to 6 months following completion of treatment
Social support as measured by the Perceived Social Support from Family scoreUp to 6 months following completion of treatment
Physical activity as measured by the Godin-Shepard Leisure-Time Physical Activity Questionnaire scoreUp to 6 months following completion of treatment
Dietary habits as measured by the Food Habits QuestionnaireUp to 6 months following completion of treatment
Sexual functioning as measured by the Sexual Experience Scale scoreUp to 6 months following completion of treatment

Secondary

MeasureTime frame
Therapist-reported fidelity/Usage of BBI as measured through logsUp to 6 months following completion of treatment
Patient-reported evaluation of the BBI as measured by the Evaluation of Topics scoreUp to 6 months following completion of treatment

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026